In CKD, once-daily empagliflozin reduced progression of kidney disease or CV death at 2 y

EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. N Engl J Med. 2023;388:117-27. 36331190.

Saved in:
Bibliographic Details
Published inAnnals of internal medicine Vol. 176; no. 3; p. JC26
Main Authors Kwong, Y Diana, Hsu, Chi-Yuan
Format Journal Article
LanguageEnglish
Published United States 01.03.2023
Subjects
Cardiovascular Diseases
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Humans
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Risk Factors
Online AccessGet more information

Cover

More Information
Summary:EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. N Engl J Med. 2023;388:117-27. 36331190.
ISSN:1539-3704
DOI:10.7326/J23-0009